StockStory Avoids United Therapeutics, Recommends Nova and Synchrony Financial as Mid-Cap Buys

StockStory on May 29, 2026, identified United Therapeutics (NASDAQ:UTHR) as a mid-cap stock to avoid, while naming Nova (NASDAQ:NVMI) and Synchrony Financial (NYSE:SYF) as buys based on valuation and growth prospects. UTHR, which develops pulmonary hypertension treatments, traded at $565.50 per share, or 12.3 times forward price-to-sales, with a $23.86 billion market capitalization. The firm cited the company as falling short without providing specific reasons in the brief. Nova, a semiconductor quality control equipment maker, commanded a 45.3 times forward price-to-earnings multiple at $508.50 a share, with a $16.08 billion market cap. Synchrony Financial, a consumer finance company powering over 73 million active accounts, traded at $70.51 per share, implying a 7.5 times forward P/E ratio and a $24.04 billion valuation. StockStory highlighted Synchrony as bullish, pointing to its partnerships with major brands like Amazon and PayPal.